Abstract
Hemostatic balance is regulated by many factors that may become perturbed by cardio-metabolic abnormalities. Indeed, patients with multiple components of the metabolic syndrome have increased risk of atherosclerosis, hemostatic disorders and thrombotic events. This review focuses on the interrelationship between the metabolic syndrome components and thrombotic and thromboembolic events, the potential underlying mechanisms that lead to metabolic and hemostatic disorders in metabolic syndrome patients, the existing therapeutics aimed at reducing major cardiovascular events, and new therapeutic approaches to address pro-coagulant states.
Keywords: Metabolic syndrome, hemostatis, thrombosis, coagulation, cardiovascular disease, diabetes, cardio-metabolic abnormalities, metabolic syndrome patients, thromboembolic events, cardiovascular risk, coronary atheroma progression, Elevated triglyceride-rich VLDL, adipocyte dysfunction, coronary heart disease (CHD)
Current Pharmaceutical Biotechnology
Title: Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Volume: 12 Issue: 9
Author(s): Laura F. Michael, Veena Rao, Patrick McCollam, Mark C. Kowala and John Wetterau
Affiliation:
Keywords: Metabolic syndrome, hemostatis, thrombosis, coagulation, cardiovascular disease, diabetes, cardio-metabolic abnormalities, metabolic syndrome patients, thromboembolic events, cardiovascular risk, coronary atheroma progression, Elevated triglyceride-rich VLDL, adipocyte dysfunction, coronary heart disease (CHD)
Abstract: Hemostatic balance is regulated by many factors that may become perturbed by cardio-metabolic abnormalities. Indeed, patients with multiple components of the metabolic syndrome have increased risk of atherosclerosis, hemostatic disorders and thrombotic events. This review focuses on the interrelationship between the metabolic syndrome components and thrombotic and thromboembolic events, the potential underlying mechanisms that lead to metabolic and hemostatic disorders in metabolic syndrome patients, the existing therapeutics aimed at reducing major cardiovascular events, and new therapeutic approaches to address pro-coagulant states.
Export Options
About this article
Cite this article as:
F. Michael Laura, Rao Veena, McCollam Patrick, C. Kowala Mark and Wetterau John, Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281081
DOI https://dx.doi.org/10.2174/138920111798281081 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design The Clinics and Etiology of Preeclampsia
Current Women`s Health Reviews Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Current Vascular Pharmacology An Update on Potential Molecular Mechanisms Underlying the Actions of Snake Venom L-amino Acid Oxidases (LAAOs)
Current Medicinal Chemistry Coagulation Factor XIIIA (F13A1): Novel Perspectives in Treatment and Pharmacogenetics
Current Pharmaceutical Design DHA and EPA in Sickle Cell Disease Favor Clinical Improvement and Contribute to Better Quality of Life: A Qualitative Systematic Review
Current Drug Research Reviews Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Tapping into Mitochondria to Find Novel Targets for Diabetes Complications
Current Drug Targets Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry Hyaluronic Acid/Parecoxib-Loaded PLGA Microspheres for Therapy of Temporomandibular Disorders
Current Drug Delivery PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Relevance of Postprandial Lipemia in Metabolic Syndrome
Current Vascular Pharmacology Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Coronary Risk Factors in the Elderly: Their Interactions and Treatment
Current Pharmaceutical Design Chitosan Enhances Osteogenetic Potential of Ethylene-Oxide Sterilized Demineralized Bone Matrix
Current Tissue Engineering (Discontinued) Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential
Current Pharmaceutical Design